Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3386-3391

  Kollmannsberger, C ^a   Beyer, J ^a   Droz, J P ^a   Harstrick, A ^a   Hartmann, J T ^a   Biron, P ^a   Flechon A ^a   Schoffski P ^a   Kuczyk, M ^a   Schmoll, H J ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; DRUG INDUCED DISEASE; DRUG MEGADOSE; FOLLOW UP; GERM CELL TUMOR; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0031757818     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3386     Document Type: Article

References (31)

1. Ratain MJ, Rowley JD: Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes. Ann Oncol 3:107-111, 1992
2. Kollmannsberger C, Hartmann JT, Kanz L, et al: Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 124:207-214, 1998
3. Pedersen-Bjergaard J, Philip P, Olesen Larsen S, et al: Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091, 1990
4. Whitlock J, Greer J, Lukens J: Epipodophyllotoxin-related leukemia. Cancer 68:600-604, 1991
5. Bokemeyer C, Schmoll H-J: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13:283-292, 1995
6. Williams S, Birch R, Einhorn L, et al: Treatment of disseminated germ-cell tumors with cisplatin. bleomycin and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
7. Pedersen-Bjergaard J, Daugaard G, Werner Hansen S, et al: Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ-cell tumors. Lancet 338:359-363, 1991
8. Bokemeyer C, Schmoll H-J: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11:1703-1709, 1993
9. Van Leeuwen F, Stiggelbout A, van den Belt-Dusebout A, et al: Second cancer risk following testicular cancer: A follow-up study of 1.909 patients. J Clin Oncol 11:415-424, 1993
10. Roth B, Greist A, Kubilis P, et al: Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up. J Clin Oncol 6:1239-1247, 1988
11. Boshoff C, Begent R, Oliver R, et al: Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 6:5-40, 1995
12. Nichols C, Breeden E, Loehrer P, et al: Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36-40, 1993
13. Bajorin D, Motzer R, Rodriguez E, et al: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60-62, 1993
14. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 15:594-603, 1997
15. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
16. Bokemeyer C, Harstrick A, Metzner B, et al: Sequential high-dose VIP-chemotherapy plus peripheral stem cell (PBSC) support for advanced germ cell tumors. Ann Oncol 7:55, 1996 (suppl 5; abstr 259)
17. Harstrick A, Fossa A, Zasadzinski E, et al: Intensive salvage therapy for germ cell cancer consisting of two cycles of cisplatin/ etoposide/ifosfamide followed by two cycles of high-dose chemotherapy and peripheral blood stem cell transfusion. Proc Am Soc Clin Oncol 16:334a, 1997 (abstr 1195)
18. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stemcell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 12:1223-1231, 1994
19. Droz JP, Culine S, Biron P, et al: High-dose chemotherapy in germ-cell tumors. Ann Oncol 7:997-1003, 1996
20. Chevreau C, Droz JP, Pico JL, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 23:213-218, 1993
21. Biron P, Brunant-Mantigny M, Bayle J, et al: Cisplatinum-VP 16 and ifosfamide (VIC) + autologous bone marrow transplantation (ABMT) in poor prognostic non seminomatous germ cell tumors (NSGCT). Proc Am Soc Clin Oncol 8:148, 1989 (abstr)
22. Breslow NE, Day NE: Statistical Methods in Cancer Research. Vol II - The Design and Analysis of Cohort Studies. Lyon, France, IARC Scientific Publications No. 82, 1987, p 70
23. Nichols C, Roth B, Heerema N, et al: Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322:1425-1429, 1990
24. Beyer J, Kingreen D, Krause M, et al: Long-term survival of patients with recurrent or refractory germ-cell tumors after high-dose chemotherapy. Cancer 79:161-168, 1997
25. Margolin K, Doroshow J, Ahn C, et al: Treatment of germ-cell cancer with two cycle of high-dose ifosfamide, carboplatin and etoposide with autologous stem-cell support. J Clin Oncol 14:2631-2637, 1996
26. Motzer R, Mazumdar M, Bosl G, et al: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
27. Motzer R, Mazumdar M, Bajorin D, et al: High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ-cell tumors. J Clin Oncol 15:2546-2552, 1997
28. Bokemeyer C, Schmoll H-J, Kuczyk M, et al: Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst. 87:58-60, 1995
29. Sandoval C, Pui C-H, Bowman L, et al: Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors and irradiation. J Clin Oncol 11:1039-1045, 1993
30. Pui C-H, Ribeiro R, Hancock M, et al: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991
31. Nichols CR, Loehrer PJ Sr: The story of second cancers in patients cured of testicular cancer: Tarnishing success or burnishing irrelevance? J Natl Cancer Inst 89:1394-1395, 1997